Form 4: Vertex Pharmaceuticals EVP David Altshuler Reports Acquisition of Performance Shares

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the acquisition of performance shares related to performance stock unit awards.

Summary

• On February 4, 2025, David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reported the acquisition of 12,314 performance shares related to a performance stock unit award granted on February 1, 2022.
• These shares were earned based on the attainment of performance goals certified by the issuer's management development and compensation committee on February 4, 2025, and will vest on February 26, 2025.
• Additionally, Mr. Altshuler acquired 7,114 performance shares related to a performance stock unit award granted on February 7, 2024, also based on performance goal attainment certified on February 4, 2025.
• These shares will vest in installments beginning on February 17, 2025.
• Following these transactions, Mr. Altshuler beneficially owns 45,241 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects the achievement of performance goals, which is generally a good sign for the company. However, it's a routine filing and doesn't contain any groundbreaking news.

Positives

• The vesting of performance shares indicates that performance goals set by Vertex Pharmaceuticals were achieved, which could be viewed positively by investors.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects the alignment of executive incentives with company performance.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among pharmaceutical companies to incentivize executives and align their interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize performance stock units as part of their executive compensation packages.
• The specific performance metrics and vesting schedules vary depending on the company's strategic goals and industry benchmarks.

Stakeholder Impact

• The vesting of performance shares can positively impact shareholders by aligning executive interests with company performance.
• Employees may view this as a positive sign of the company's success and the achievement of its goals.

Key Dates